Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Overview
DESCRIPTION | |
Species Reactivity | Human PD-L1 |
Immunogen | recombinant human PD-L1 extracellular domain |
Purity | > 95% determined by SDS-PAGE |
Formulation | 1x PBS, pH7.4 |
Size | 50µl (concentration 1mg/mL) |
APPLICATION | |
ELISA | |
IHC | 1:1000 |
Western Blot | 1:1000 - 1:3000 |
Research Use or Further Manufacturing Only. | |
PREPARATION AND STORAGE | |
Preparation | Monoclonal antibody is produced by immunizing rabbit with recombinant human PD-L1 extracellular domain and purified using protein A resin. |
Storage | This antibody is shipped at 4 oC. This product is stable for 12 months from date of receipt when stored at -20oC to -70oC. Avoid freeze/thaw cycles |
BACKGROUND
Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1- PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies |